NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Cross Above 50 Day Moving Average of $0.00

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBYGet Rating)’s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.00 and traded as high as $0.22. NovaBay Pharmaceuticals shares last traded at $0.19, with a volume of 939,613 shares trading hands.

Separately, Zacks Investment Research downgraded shares of NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 18th.

The company has a market cap of $9.87 million, a P/E ratio of -1.13 and a beta of 3.47.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBYGet Rating) last announced its quarterly earnings results on Tuesday, March 29th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The business had revenue of $2.64 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 67.65%. Equities analysts forecast that NovaBay Pharmaceuticals, Inc. will post -0.21 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of NBY. Millennium Management LLC purchased a new stake in NovaBay Pharmaceuticals in the 4th quarter worth approximately $34,000. Renaissance Technologies LLC raised its position in shares of NovaBay Pharmaceuticals by 57.5% during the 1st quarter. Renaissance Technologies LLC now owns 201,222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 73,500 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of NovaBay Pharmaceuticals during the 3rd quarter valued at $28,000. Finally, Citadel Advisors LLC raised its position in shares of NovaBay Pharmaceuticals by 25.8% during the 2nd quarter. Citadel Advisors LLC now owns 91,917 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 18,859 shares in the last quarter. Institutional investors and hedge funds own 2.64% of the company’s stock.

NovaBay Pharmaceuticals Company Profile (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Recommended Stories

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.